Asiri Aktif Mesane Tedavisinde Karma Etkili Ajanların Etki Mekanizmasi ve Avantajlari

Karakeçi, Ahmet; Onur, Rahmi

doi:10.5152/knb.2016.05

Cited by 1 publication

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[27][28][29] It has been shown that antimuscarinics may cause undesirable effects such as dizziness, drowsiness, and insomnia, 30 while Propiverine has been shown to increase the quality of life without affecting cognitive functions. 16 In addition, many studies have reported that propiverine may be contraindicated only in unexamined angle-closure glaucoma patients in terms of ophthalmologic safety. 13 It is reported that antimuscarinic drugs have similar side-effect profiles and the most common complaint is dry mouth.…”

Section: Discussionmentioning

confidence: 99%

“…In other words, propiverine can also inhibit the purinergic mechanism, which is another factor responsible for detrusor contraction. 16 Since propiverine can be considered a weak inhibitor of cytochrome P450 (CYP3A4), significant increases in the concentrations of other drugs metabolized by this pathway are not expected with concomitant use with propiverine. 12 The pharmacokinetics of propiverine were not altered in patients with severe renal impairment (CC<30 mL/min) or mild to moderate liver failure from fatty liver disease, and in elderly patients (60-85 years) compared to young healthy adults.…”

Section: Nocturiamentioning

confidence: 99%

“…45 Propiverine has been shown to improve quality of life without affecting cognitive functions. 16 In addition, Uchiyama et al evaluated the elderly (71± 8.2 years old) and patients with neurological diseases (Multiple brain infarcts, Parkinson's disease, Alzheimer's disease) staying in nursing homes and hospitals in terms of cognitive parameters before and after propiverine treatment, and no significant changes were observed in post-void residual measures, higher brain function scales, parameters, and motor functions measured by CIBIC (Clinician's Interview-Based Impression of Change). 46 Patients with detrusor hyperreflexia may be treated with an anticholinergic agent, including propiverine.…”

Section: Overview Of Literaturementioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of propiverine in patients with overactive bladder and neurogenic detrusor overactivity

Faikoglu¹,

Saygisever-Faikoglu²,

Ozcan³

et al. 2022

PPIJ

View full text Add to dashboard Cite

Purpose:The purpose of this review is to evaluate the efficacy and safety of propiverine in pediatric and adult patients, which is used in the symptomatic treatment of urgency urinary incontinence and urinary frequency and/or urinary incontinence in patients with neurogenic detrusor overactivity due to overactive bladder or spinal cord injuries.Method: Literature was retrieved by a PubMed search, using different combinations of pertinent keywords (e.g., propiverine, overactive bladder, neurogenic detrusor overactivity), without any limitations in terms of the publication date and language. Papers that assessed the therapeutic efficacy and tolerability of propiverine in patients with overactive bladder or neurogenic detrusor overactivity were selected for inclusion according to their relevance for the topic, as judged by the authors. Results:Propiverine is reported to be a significantly effective and safe treatment option in adult and pediatric patients with overactive bladder or neurogenic detrusor overactivity. It is observed that propiverine provides an increase in life quality without affecting cognitive functions, and may be a safe treatment option, except for patients with angleclosure glaucoma, who have not been examined in terms of ophthalmological reliability. It was observed that no changes were observed in cardiac parameters in patients receiving propiverine treatment, and there was no clinically significant difference in the incidence of side effects between the two groups in studies comparing elderly and young patients. Propiverine is recommended by the pediatric committee at the International Incontinence Consultation with the highest level of evidence (1B/C) of all anticholinergics. Conclusion:Propiverine is an effective and safe treatment option that can be the first choice in the symptomatic treatment of both adult and pediatric patients with overactive bladder or neurogenic detrusor overactivity, with its high efficacy and significantly higher tolerability.

show abstract